HedgeRoll - Value Investing and After Tax Returns
  • HedgeRoll
  • Contact
  • Research

hedgeroll

In Search of After-Tax returns

Best Books For Biotech Investors

12/17/2014

0 Comments

 
Occasionally people ask me for book recommendations regarding biotechnology investing. I always recommend the following two books:

Edit: Since the original publication of these recommendations, a new book has been published. The Pharmagellan Guide to Biotech Forecasting and Valuation is my new #1 recommendation.
​
Picture
Back to the original post.....

The first book I always recommend: ​
The Biotech Traders Handbook
I used to give this book to interns on their first day. It has two parts, the first is a concise and non-technical introduction to the space. My interns could typically read that in an hour or two. The second part is an introduction to option trading in biotechs, and is appropriate for those who want to step their trading up beyond straight equity.
Picture
The second book:
Biotechnology Valuation: An Introductory Guide
Have you ever been invested in a biotech company and seen it go down after it's drug was approved by the FDA? If you go to Yahoo message boards afterword, you will see investors saying "I just don't get it" and blaming short sellers. In reality, unsophisticated investors don't get valuation. Most likely, the stock was overvalued going into the FDA approval, and now its getting back to reality. This book with teach you rNPV modeling of pipelines, so you are not surprised again.
Picture
Full disclosure: I recently became a contributor at Chimera Research Group. The author of Biotech Traders Handbook, Tony Pelz, is a founder of Chimera. However, I have been recommending the book for years.

Sign up for the emails.

I will only email you when I have something interesting to share.
Email Marketing You Can Trust
0 Comments

Ebola, Obama, and how Biotech is going to Benefit from A Senate Bill

12/8/2014

0 Comments

 
One my favorite things in the market is finding obscure situations that elude conventional analysis. My latest interest is the pricing of Priority Review Vouchers.

A little background:  The 2007 Food and Drug Administration Amendments Act (FDAAA) created Priority Review Vouchers (PRV). The purpose of the vouchers are to incentivize drug development for neglected tropical diseases which can represent a limited commercial opportunity. 

These vouchers reduce the FDA review time for drug approvals from 10 months to 6 months, and are awarded by the FDA to a company that obtains approval for a treatment for a neglected tropical disease.

Things got interesting in November when Gilead Sciences (GILD) paid $125,000,000 to purchase one of these vouchers from Knight Therapeutics (GUD/CN).

How many of these vouchers exist? According to Evaluate Pharma, only four have been issued, with three being of the Neglected Tropical Disease type, and one being for Rare Pediatric Disease. The two programs currently have some important differences, so for the purposes of this article we are focusing on  Neglected Tropical Diseases. Below are the status of all four: 
Picture
Things got even more interesting when the Senate voted for the Adding Ebola to the FDA Priority Review Voucher Program Act, which would change three elements of the  Neglected Tropical Disease Priority Review Voucher program:
  1. Add Filovirus, which includes  Ebola,  Marburg, and Lloviu to the program.
  2. Shorten the notice period to use the vouchers from 365 days to just 90 days. 
  3. Allow the re-sale of the vouchers an unlimited number of times. The current limit is once.

The bill has broad bipartisan support, and is expected to be passed by the House and  signed into law by President Obama. While the headline is about Ebola, we are interested in points two and three, which would bring the neglected tropical disease program more in line with the rare pediatric disease program.

The reason we are interest in the time frame shift ( from 365 days to 90 days) is because it impact the value of the PRVs. Simply put, the sooner a firm can see revenue from a drug, the more its worth today. This is especially true if one were to factor in a the competitive landscape, where the first mover advantage can be critical. 

To estimate the impact of this shortened time frame I ran the back-of-the-envelope calculations below:
Picture
The take away here is once the Adding Ebola to the FDA Priority Review Voucher Program Act becomes law, the Neglected Tropical Disease PRVs will be come more valuable based on the reduced time frame alone. As for the discount rate, I came to 15% via a sophisticated method known as "from thin air". Yes, I can already hear you CFAs saying "you should use the WACC". To that I say drug development is a risky business and you should be more conservative in your modeling assumptions.

An additional factor that will drive up the value of PRVs is the lifted re-sale restrictions. Previously, if you bought the PRV you had to use it, as only one re-sale was allowed. However, with no re-sale restrictions, the pool of capital that could potentially purchase a voucher is much larger. One could see a healthcare firm with a large amount of capital scoop one of these up with the intent of selling it later. The liquidity premium is a real thing, and in this case I'm going to give it a conservative 2.5% liquidity premium, bringing the value to $142.3M. 

This brings the total gain from the legislation to +$17.3M per PVR. While this amount isn't going to move the needle for giants like J&J or Gilead, it certainly is material for a firm like Knight Therapeutics, which has a market cap of just $540M (Canadian). Ask them if they would like another $17 million for the PRV they sold to Gilead.

It is no surprise the Biotechnology Industry Organization (BIO) has come out in support of the bill.

Of course there are additional factors at play here, as I said this a back of the envelope exercise. For example, from a drug developers perspective, much of the value is derived from the drug and indication for which the priority review will be used. Furthermore, as the FDA issues more PRVs over time, the increased supply may drive down prices. One could also Again there are many factors that firms buying and selling will consider next time these trade hands, but I digress.

Those who want to learn more about Ebola can check out the classic The Hot Zone: The Terrifying True Story of the Origins of the Ebola Virus.

One last thing, once Filoviruses (Ebola et al) gets added to the list of indications PRVs can be used on, what does that list look like? See below:
Picture
0 Comments

Top 2 Oncology Companies Owned By Biotech Hedge Funds

12/1/2014

0 Comments

 
My favorite way to generate investment ideas is reviewing Form 13F filings from great healthcare investors. I first read of this approach years ago in Mebane Faber's book. 

If searching for investment ideas is like looking for a needle in a haystack, then 13F filings are a stack of needles.

I later found out the great Mohnish Pabrai  also uses filings for idea generation. 

I've backtested the filings of 60+ healthcare focused investors, and I have ten that are worth following. These include the well known Perceptive Advisors, and Baker Bros Advisors, but also more under- the-radar firms such as Broadfin Capital. It is important that 13Fs are the beginning of an investment research process. Due diligence is still critical.

Some of my most successful biotechnology stock picks generated by 13Fs have been in the oncology space. An example would be when I bought Pharmacyclics (PCYC) at $19 in February 2012, and held it for a multibagger.

The most recent set of 13Fs were as of September 30, 2014. Here are the two most popular oncology stocks held by my group of hedge funds.  

Pharmacyclics (PCYC): A long time favorite of Baker Bros., also owned by Perceptive and BB Biotech, as of September 30, 2014. Ibruvica is currently approved for Mantle cell lymphoma (MCL)  and Chronic lymphocytic leukemia (CLL)  patients who have received at least one prior treatment. 
Picture
PCYC is in growth mode, after having Ibruvica approved, the company swung into profitability during the 3rd Quarter of 2014. Analysts expect 37% year over year revenue growth in 2015. 

At the upcoming ASH conference the company will be presenting data in the effort to get indication expansion into B-Cell Lymphoma. 

Investors are clearly very excited about the growth story here, as the stock currently trades at 11x next years estimated revenue. The bear case revolves around next generation competitors to Ibruvica.
Picture
The stock does appears to be near full value, as analyst average price target is $161, which is only 16% higher than current prices.




Celgene (CELG): Owned by RA Capital, Orbimed, BB Biotech, and Perceptive as of September 30,  2013. Celgene is a major player in the oncology space and has products approved for many indications. Revlimid represents 66% of Celgene's revenue. It is approved for  Multiple myeloma (MM), myelodysplastic syndromes (MDS), and Mantle cell lymphoma (MCL). Furthermore, there will be many presentations at ASH 2014.

It is worth noting this company has a less concentrated product portfolio than PCYC, with a single product on the market.

Analyst are expecting very strong growth from CELG specifically from their Revlimid, and  Abraxane franchises. Celgene's IR site tracks analyst estimates, and it states that EPS growth of 32% is expected in 2015.
Picture
CELG investors have been impressed with the growth story. The company trades as 9.7x forward sales estimates, and 25x forward EPS estimates. These valuations  could be justified if the firm can pull off its growth plans without any miss-steps. 

No value investor would call this either PCYC or CELG "cheap".
Picture
Most analyst would not call CELG cheap either. The current analyst price target is $116, which is about where the stock trades now. Investors would be wise to wait for a pull back, or wait for analyst upgrades.
Picture
Disclosure: I own none of the stocks mentioned in these articles and have no plans on buying them in the next 48 hour

Data: Ycharts.com/Morningstar and 4-Traders.com/Thompson Reuters.

0 Comments
    Picture
    This is the personal blog of Emory Redd.

    This blog is not investment advice. This is not a solicitation to invest. Don't take candy from strangers.
    Follow @Emory_R
    View my profile on LinkedIn
    BEST OF HEDGEROLL
    ACHILLION AND RA CAPITAL: MY FAVORITE TRADE

    SALIX INVESTORS LOOKING FOR A BUYOUT SHOULD BE CAUTIOUS; MORE ACCOUNTING PROBLEMS AHEAD

    BIOTECH AS BUFFETT'S WONDERFUL BUSINESS
    Get Email Updates

    Categories

    All
    13D
    13F
    13G
    Abingworth
    Accounting
    Accounting Fraud
    Achillion ACHN
    Activist
    AGN
    Aig
    Alphasimplex Group
    American Express
    Andrew Lo
    ANTH
    Anthera Pharmaceuticals
    Anthony Scaramucci
    Arbitrage
    ARC-520
    Argonaut Capital Management
    Arrowhead Research
    Artemis
    ARWR
    ASH 2014
    Avenue Capital
    AXP
    Baker Bros. Advisors
    Baker Brothers
    Barton Biggs
    Baupost Group
    BB Biotech
    Bear Stearns
    Beneish M-Score
    BenjaminJGarber.com
    Bershire Hathaway
    Bill Gross
    Biotech Hedge Fund
    Biotechnology
    Biotech Trader Handbook
    Biotech Valuation
    Black Swan
    BMY
    Bob Treue
    Bonds
    Books
    Broadfin Capital
    Bruce Greenwald
    Bubble
    Capital Returns Management
    Carl Icahn
    Carlos Slim
    Carnegie Mellon
    Celgene (CELG)
    Channel-stuffing
    Charlie Munger
    China
    Chris Levett
    Circle-of-competence
    Clive Capital
    Coca-Cola Company
    Coke KO
    Columbia Business School
    Commodities
    Contrarian Trades
    Credit
    Credit Bubble
    Cta
    Currency
    Daniel Gold
    Data Mining
    David Einhorn
    David Gerstenhaber
    David Harding
    David Tepper
    Davita Inc
    D.E. Shaw
    Deutsche Bank
    Donald Trump
    Dunn & Bradstreet DNB
    Dva
    Earnings Manipulation
    Eric Sprott
    Fabozzi-books
    Fed Day
    Federated Investors
    Fees
    Fig
    Fixed Income
    Form 4
    Fortress Investment Group Llc
    Fund Of Funds
    Gartmore
    GILD
    Gilead
    Glaxosmithkline
    Global Macro
    Gold
    Goldman Sachs
    Gotham Capital
    GSK
    HBV
    HCV
    Hedge Fund Start-up
    Hepatitis B
    Hepatitis C
    HIV
    Humor
    IBM
    IgA Nephropathy
    Inflation
    Insurance Companies
    Intellectual Property
    International Business Machines
    Izzy Englander
    Jeffrey Ubben
    JNJ
    Joel Greenblatt
    John Paulson
    Johnson & Johnson
    John W Henry
    Julian Robertson
    Kkr
    KO
    Leon Cooperman
    Loeb
    Long Term Capital Management
    Lupus
    M&A
    Man Group
    Marc Lasry
    Mellon
    Michael Bloomberg
    Michael Burry
    Michael Lewis
    Michael L Roirdan
    Michael Novogratz
    Michael Steinhardt
    Millennium Partners
    Moody's MCO
    Mr. T
    MRX
    Municipal Bonds
    Music
    Nassim Taleb
    Obama
    Occupy Wall Street
    Oil
    Omega Advisors
    Oncology
    Orbimed Advisors
    Orphan Disease
    Palo Alto Investors
    Paul Tudor Jones Iii
    Perceptive Advisors
    Pershing Square
    PG
    Pharmacyclics (PCYC)
    Phil Falcone
    Point State Capital
    Private Equity
    Procter & Gamble
    Quantitative Easing
    Quants
    QVT Financial
    RA Capital
    Redmile Group
    Return On Invested Capital
    Rob Bobman
    Robert Shiller
    Rob Goldstein
    ROIC
    Salix Pharmaceuticals SLXP
    Sanofi-Aventis
    Sebastian Mallaby
    Sec
    Seeding
    Seth Klarman
    Shorts
    Short Selling
    Short Selling Books
    Silver
    Skybridge
    SLXP
    SNY
    Stanley Druckenmiller
    Statistical Arbitrage
    St Joe Company
    Sub-Prime
    Ted Weschler
    The Barnegat Fund
    Thomas Mellon
    Traxis Partners
    Twitter
    Twitter Hedge Fund
    Valeant
    ValueAct
    Value Investing
    Vanderbilt
    VHCP Management
    Victor Niederhoffer
    VRX
    Warren Buffett
    Warren Buffett Letters
    Wells Fargo
    Wfc
    When Stocks Crash Nicely
    William Ackman
    Winton Capital Management
    Wonderful Business
    Yale University

    Archives

    December 2016
    August 2016
    June 2016
    May 2016
    April 2016
    March 2016
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    December 2014
    November 2014
    October 2014
    August 2014
    April 2014
    August 2013
    October 2012
    September 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011
    April 2011
    March 2011
    February 2011
    January 2011
    December 2010
    November 2010
    October 2010
    September 2010

    RSS Feed

Powered by Create your own unique website with customizable templates.
  • HedgeRoll
  • Contact
  • Research